Heart failure & cardiomyopathies
Serum Potassium Level and Mineralocorticoid Receptor Antagonist Dose in a Large Cohort of Chronic Heart Failure Patients
Authors' conclusion
In this large registry of real-world chronic HF patients, both an increase in serum potassium and hyperkalaemia were associated with a lower odds of receiving the guideline-recommended MRA dose.
Study context
- Population
- Chronic heart failure (HF) patients with LVEF ≤40% at 34 Dutch outpatient HF clinics, 2013–2016
- Participants
- 5,346 patients34 Dutch HF clinics
- Exposure
- Serum potassium >5.0 vs 4.0–5.0 vs <4.0 mmol/L
- >5.0 mmol/Ln = 399
- Outcome
- Receipt of ≥100% of the target MRA dose (50 mg)
Methodological detailsmulticentre, registry, multivariable logistic regression
- Multicentre
- Registry
- Multivariable logistic regression
Main finding
As reported in the abstract
≥100% of target MRA dose (50 mg)
Odds ratio (95% CI)P value
>5.0 mmol/Lvs 4.0–5.0 mmol/L
0.38(0.15–0.97)
P = 0.044One unit increase in serum potassium
0.69(0.49–0.98)
P = 0.036Observational data: associations, not effects.
Further findings
Serum potassium, hyperkalaemia and MRA use (whole cohort)
- Mean serum potassium
- 4.4 ± 0.5 mmol/L
- Hyperkalaemia (>5.0 mmol/L)
- 399 (7.5%)
- MRA use
- 3091 (58.1%)
Original publication
Serum Potassium Level and Mineralocorticoid Receptor Antagonist Dose in a Large Cohort of Chronic Heart Failure Patients. ESC Heart Fail. Published 3 February 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →